This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

David C. Cumming, MD; James C. Yang, MD; Robert W. Rebar, MD; Samuel S. C. Yen, MD

JAMA. 1982;247(9):1295-1298.

Abstract
Clinical and endocrine evaluations of 39 patients with hirsutism were performed to determine the effectiveness and site(s) of action of an antiandrogenic compound, spironolactone. Treatment with spironolactone at a dose of 200 mg/day resulted in a clear beneficial effect on the quantity and quality of facial hair growth in 19 of 20 patients with moderate to severe hirsutism. Regression of hirsutism in terms of diameter, density, and the rate of facial hair growth was noticeable within two months. The maximal effect was observed at six months and was maintained at 12 months of treatment. Spironolactone was equally effective in reducing hirsutism in women with polycystic ovary syndrome and idiopathic hirsutism. These clinical observations were associated with a prompt and sustained reduction in levels of androgen of ovarian origin without affecting levels of adrenal androgen and cortisol. Apart from diuresis, which was limited to the first few days of treatment, there were no discernible side effects during the one year of this study. Our results indicate that spironolactone is a highly effective and safe agent for the treatment of hirsutism through its inhibitory action on both ovarian androgen secretion and peripheral androgen action.

(JAMA 1982;247:1295-1298)

Author Affiliations
From the Department of Reproductive Medicine and the General Clinical Research Center (Drs Cumming, Yang, Rebar, and Yen), University of California, San Diego, School of Medicine, La Jolla. Dr Cumming is now with the Departments of Obstetrics and Gynecology and Medicine, Division of Endocrinology, University of Alberta, Edmonton, Alberta.

Footnotes
Reprint requests to Department of Reproductive Medicine T-002, University of California, San Diego, School of Medicine, La Jolla, CA 92093 (Dr Yen).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Visually scoring hirsutism
Yildiz et al.
Hum Reprod Update 2009;0:dmp024v1-dmp024.
ABSTRACT | FULL TEXT  

Comparison of Efficacy of Spironolactone with Metformin in the Management of Polycystic Ovary Syndrome: An Open-Labeled Study
Ganie et al.
J. Clin. Endocrinol. Metab. 2004;89:2756-2762.
ABSTRACT | FULL TEXT  

Role of Hormones in Pilosebaceous Unit Development
Deplewski and Rosenfield
Endocr. Rev. 2000;21:363-392.
ABSTRACT | FULL TEXT  

New Activity of Spironolactone: Inhibition of Angiogenesis In Vitro and In Vivo
Klauber et al.
Circulation 1996;94:2566-2571.
ABSTRACT | FULL TEXT  

Androgens and Therapeutic Aspects of Antiandrogens in Women
Diamanti-Kandarakis et al.
Reproductive Sciences 1995;2:577-592.
ABSTRACT  

The Polycystic Ovary Syndrome: Pathogenesis and Treatment
Barnes and Rosenfield
ANN INTERN MED 1989;110:386-399.
ABSTRACT  

Hirsutism
RITTMASTER and LORIAUX
ANN INTERN MED 1987;106:95-107.
ABSTRACT  

Topical Antiandrogens: What Use in Dermatology?
Lucky
Arch Dermatol 1985;121:55-56.
ABSTRACT  

Antiandrogenic Effects of Topically Applied Spironolactone on the Hamster Flank Organ
Weissmann et al.
Arch Dermatol 1985;121:57-62.
ABSTRACT  

Hirsutism
Braithwaite and Jabamoni
Arch Dermatol 1983;119:279-284.
ABSTRACT